Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand

Dorthe Skovgaard, Morten Persson, Andreas Kjaer*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftReviewForskningpeer review

10 Citationer (Scopus)

Abstract

Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.

OriginalsprogEngelsk
TidsskriftPET Clinics
Vol/bind12
Udgave nummer3
Sider (fra-til)311-319
Antal sider9
ISSN1556-8598
DOI
StatusUdgivet - 2017

Citationsformater